Systemic Targeted Therapies in Patients with Relapsed/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A...

Area of Science:

• Oncology
• Dermatology
• Hematology

Background:

• Cutaneous T-cell lymphomas (CTCL) are a diverse group of non-Hodgkin lymphomas.
• Early-stage CTCL is often managed with topical treatments, while advanced stages require systemic therapies.
• Systemic antibody-targeted therapies are crucial for advanced, relapsed, or refractory CTCL.

Purpose of the Study:

• To evaluate real-world outcomes of advanced-stage CTCL patients treated with systemic targeted therapies.
• To compare the effectiveness of mogamulizumab, brentuximab vedotin, and alemtuzumab in a clinical setting.
• To highlight the complexities of managing advanced CTCL with current systemic treatments.

Main Methods:

• Retrospective cohort case series of 27 patients from Aarhus University Hospital (2013-2023).
• Patients had relapsed/refractory advanced-stage CTCL, primarily Sézary syndrome or mycosis fungoides.
• Analysis of outcomes for patients receiving mogamulizumab, brentuximab vedotin, or alemtuzumab.

Main Results:

• Overall response rates were 78% for mogamulizumab, 65% for brentuximab vedotin, and 61% for alemtuzumab.
• Median time to progression was 2.5 months for mogamulizumab, 4 months for brentuximab vedotin, and 11 months for alemtuzumab.
• Six patients received more than one systemic targeted treatment, indicating complex treatment pathways.

Conclusions:

• Systemic targeted therapies are effective in managing advanced-stage CTCL.
• Alemtuzumab, especially in a low-dose protocol, shows particularly promising results for advanced CTCL.
• The study provides insights into clinical practice complexities for advanced CTCL management.